Skip to content
Kalpvruksh Markets
Offline Log in

SENORESNSEOffline

SENORES PHARMACEUTIC · INE0RB801010 · Small Cap · #847
1,187.90+50.90 (+4.48%)last close · 05 Nov 2026
Prev close
1,137.00
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹4,192 cr
52-week range · to 05 Nov 2026710.251,550.9

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

SENORES is 23% below its 52-week high, above its 200-day average — a Small Cap company, #847 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 200-day average · below its 20 / 50-day averages · 23% below its 52-week high
  • −8.3% vs Nifty 500
  • traded value 2.8× usual · delivery 39% vs 45% usual
  • FPI −0.6 pp · DII +1.1 pp · MF schemes in Sept 2026: 10 bought, 1 cut · promoter pledge 2.8% · quarter ended 2026-09-30
  • nothing scheduled or restricting

How big is it?

six-month average market cap

Market capitalisation
₹4,192 cr
Rank
#847
Cap band
Small Cap
Nearest cut-off — Mid / Small
−87.74% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
1.7×
median 93,409
Delivered
1,61,363
Of volume
44%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week−2.6%−8.0 pts—
1 month−14.5%−18.2 pts—
3 months−10.2%−8.3 pts—
6 months+29.7%+29.2 pts—
1 year+53.2%+57.3 pts—

Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
−4.5%
below
vs 50-day average
−12.0%
below
vs 200-day average
+6.0%
above
ATR (14)
5.9%
typical daily range
Volatility
55%
1 month, annualised
Beta
0.96
vs Nifty 500, 1 year
Traded value
2.8×
vs usual
Delivery
39%
usual 45%
From the 52-week high
−23.4%
place in range 57% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters45.8%45.8%45.8%45.8%
FPI3.4%3.6% +0.36.6% +3.06.0% −0.6
Mutual funds4.9%5.1% +0.26.6% +1.57.4% +0.8
Other DII4.4%4.6% +0.13.2% −1.33.5% +0.3
Individuals32.0%31.6% −0.329.2% −2.429.4% +0.1
Others9.6%9.3% −0.38.6% −0.77.9% −0.6

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
2.8%
Of all shares
1.3%
Jun 25 noneSep 25 noneDec 25 1.9%Mar 26 1.9%Jun 26 2.8%Sep 26 2.8%

Holders

Sep 26

All shareholders
42,642
Individuals
40,110

Indian passive funds’ stake

2026-06-30

Of free float
0.00%
Of all shares
0.00%
Schemes
2
Days to unwind
<0.1
at 100% of volume

1,008 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
16
2 index · 14 active
Bought more
3
Sold some
3
FundSharesChangeDid
HSBC Multi Cap Fund-Reg(G)Active+1,60,503+86.6%bought
HSBC Small Cap Fund-Reg(G)Active+2,09,794+52.6%bought
Mahindra Manulife Large & Mid Cap Fund-Reg(G)Active−1,06,337−19.7%sold
Mahindra Manulife Balanced Advantage Fund-Reg(G)Active−17,000−15.9%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 26226410+12.0%₹400 cr
Aug 26161641−4.9%₹369 cr
Jul 26167404+8.5%₹354 cr
Jun 26135323+32.5%₹332 cr
May 26114221+23.2%₹211 cr
Apr 2683220−9.4%₹137 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Insider trades

SEBI PIT disclosures filed with NSE

Promoter group
No market buy or sell
Directors & KMP
No market buy or sell
Others
No market buy or sell
Latest 43 of 92 disclosures
0 selected
10 Aug 2026ASHOKKUMAR VIJAYSINH BAROTPromoterBuy30,000₹00.08%Off Market
10 Aug 2026DHANANJAY ASHOKKUMAR BAROTPromoter GroupSell30,000₹00.01%Off Market
10 Aug 2026DHANANJAY ASHOKKUMAR BAROTPromoter GroupSell30,000₹00.01%Off Market
10 Aug 2026ASHOKKUMAR VIJAYSINH BAROTPromoterBuy30,000₹00.08%Off Market
10 Aug 2026DHANANJAY ASHOKKUMAR BAROTPromoter GroupSell30,000₹00.01%Off Market
10 Aug 2026ASHOKKUMAR VIJAYSINH BAROTPromoterBuy30,000₹00.08%Off Market
28 Mar 2026Renosen Pharmaceuticals Private LimitedPromoter GroupBuy7,39,000₹60.01 cr63.16%Others
28 Mar 2026Sangeeta Mukur BarotPromoter GroupBuy61,500₹4.99 cr5.26%Others
28 Mar 2026Ashokbhai Vijaysinh BarotPromotersBuy1,23,000₹9.99 cr10.51%Others
28 Mar 2026Swapnil Jatin ShahPromotersBuy1,97,000₹16 cr16.84%Others
28 Mar 2026Viraj Ashokkumar BarotPromoter GroupBuy49,500₹4.02 cr4.23%Others
13 Feb 2026Renosen Pharmaceuticals Private LimitedPromoter GroupPledge Revoke4,00,000₹31.34 cr5.90%Revokation of Pledge
13 Feb 2026Espee Therapeutics LLPPromoter GroupPledge4,00,000₹31.34 cr1.07%Pledge Creation
31 Dec 2025Renosen Pharmaceuticals Private LimitedPromoter GroupBuy6,000₹0.49 cr5.90%Market Purchase
17 Dec 2025Renosen Pharmaceuticals Private LimitedPromoter GroupBuy4,000₹0.32 cr5.89%Market Purchase

Sums count buys and sells of equity (market and off-market); pledges are listed but not summed. From NSE’s filings: the archive to 2 May 2026, its XBRL filings since (NSE circular NSE/CML/2026/12). A filing describes what was done, not why.

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Senores Pharmaceuticals Limited has submitted to the Exchange Outcome of board Meeting held on October 29, 2026
    29 Oct 2026
  • Board outcome
    Senores Pharmaceuticals Limited has informed the Exchange that the Board of Directors of the Company at their Meeting held today i.e., Tuesday, October 13, 2026, approved the following:
    13 Oct 2026
  • Board outcome
    Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 26, 2026.
    27 Aug 2026
  • Scheme / acquisition
    Acquisition of 'to be incorporated companies'-XBRL SENORES PHARMACEUTICALS LIMITED has informed the Exchange regarding Acquisition of to be incorporated companies
    27 Aug 2026
  • Board outcome
    Senores Pharmaceuticals Limited has submitted to the Exchange outcome of Board Meeting dated July 27, 2026
    27 Jul 2026
  • Board outcome
    Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on July 27, 2026.
    27 Jul 2026

Latest shown; 7 in six months on all disclosures.

SENORES: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.